Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer Outcomes.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 28630213.
- Also identified by DOI 10.1158/1078-0432.CCR-17-1306.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The most commonly used method for dose finding, the 3 + 3, has poor performance. New adaptive designs are more efficient. Nevertheless, they have reached a maximum performance level, and further improvement requires either larger sample sizes or outcomes measures richer than the simplistic severe toxicity measured at cycle 1. <i>Clin Cancer Res; 23(15); 3977-9. ©2017 AACR</i><i>See related article by Yan et al., p. 3994</i>.
Medical subject headings
- Dose-Response Relationship, Drug
- Neoplasms